In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research Report), with a price target of $7.00. The company’s shares opened today at $3.60.
According to TipRanks, Pantginis is an analyst with an average return of -8.7% and a 39.68% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Cytokinetics, and PDS Biotechnology.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Armata Pharmaceuticals with a $7.00 average price target.
See the top stocks recommended by analysts >>
ARMP market cap is currently $99.76M and has a P/E ratio of -2.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More on ARMP:
